Lakshmi Nayak, MD, is the director of the Center for Central Nervous System Lymphoma and a senior physician at Dana-Farber Cancer Institute. She is also an associate professor of neurology at Harvard Medical School.

Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: Efficacy and safety from the phase II PROSPECT study.

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Dr. Lakshmi Nayak presents results from the Phase II PROSPECT study, demonstrating that tirabrutinib monotherapy yields a 66.7% overall response rate and a manageable safety profile in patients with relapsed or refractory primary central nervous system lymphoma, supporting its potential as an effective treatment option in this challenging population.

Tirabrutinib for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma: Efficacy and Safety From the Phase II PROSPECT Study